title: High titers of mucosal and systemic anti-PrP antibodies abrogate oral prion infection in mucosal-vaccinated mice.
abstract: Significant outbreaks of prion disease linked to oral exposure of the prion agent have occurred in animal and human populations. These disorders are associated with a conformational change of a normal protein, PrP(C) (C for cellular), to a toxic and infectious form, PrP(Sc) (Sc for scrapie). None of the prionoses currently have an effective treatment. Some forms of prion disease are thought to be spread by oral ingestion of PrP(Sc), such as chronic wasting disease and variant Creutzfeldt-Jakob disease. Attempts to obtain an active immunization in wild-type animals have been hampered by auto-tolerance to PrP and potential toxicity. Previously, we demonstrated that it is possible to overcome tolerance and obtain a specific anti-PrP antibody response by oral inoculation of the PrP protein expressed in an attenuated Salmonella vector. This past study showed that 30% of vaccinated animals were free of disease more than 350 days post-challenge. In the current study we have both optimized the vaccination protocol and divided the vaccinated mice into low and high immune responder groups prior to oral challenge with PrP(Sc) scrapie strain 139A. These methodological refinements led to a significantly improved therapeutic response. 100% of mice with a high mucosal anti-PrP titer immunoglobulin (Ig) A and a high systemic IgG titer, prior to challenge, remained without symptoms of PrP infection at 400 days (log-rank test P<0.0001 versus sham controls). The brains from these surviving clinically asymptomatic mice were free of PrP(Sc) infection by Western blot and histological examination. These promising findings suggest that effective mucosal vaccination is a feasible and useful method for overcoming tolerance to PrP and preventing prion infection via an oral route.
authors.affiliation: Department of Neurology, New York University School of Medicine, New York, NY 10016, USA.
authors.forename: F
authors.initials: F
authors.lastname: Goñi
authors.forename: F
authors.initials: F
authors.lastname: Prelli
authors.forename: F
authors.initials: F
authors.lastname: Schreiber
authors.forename: H
authors.initials: H
authors.lastname: Scholtzova
authors.forename: E
authors.initials: E
authors.lastname: Chung
authors.forename: R
authors.initials: R
authors.lastname: Kascsak
authors.forename: D R
authors.initials: DR
authors.lastname: Brown
authors.forename: E M
authors.initials: EM
authors.lastname: Sigurdsson
authors.forename: J A
authors.initials: JA
authors.lastname: Chabalgoity
authors.forename: T
authors.initials: T
authors.lastname: Wisniewski
mesh_terms: D000284:Administration, Oral; D000818:Animals; D000906:Antibodies / Q000097:blood*; D015153:Blotting, Western; D001921:Brain / Q000473:pathology; D004797:Enzyme-Linked Immunosorbent Assay; D007070:Immunoglobulin A / Q000097:blood / Q000276:immunology; D007074:Immunoglobulin G / Q000097:blood / Q000276:immunology; D051379:Mice; D011328:Prions / Q000276:immunology*; D012608:Scrapie / Q000473:pathology / Q000517:prevention & control*; D014611:Vaccination / Q000379:methods; D014612:Vaccines / Q000008:administration & dosage* / Q000276:immunology; D014614:Vaccines, Synthetic / Q000008:administration & dosage / Q000276:immunology
chemical_list: D000906:Antibodies; D007070:Immunoglobulin A; D007074:Immunoglobulin G; D011328:Prions; D014612:Vaccines; D014614:Vaccines, Synthetic